CanaQuest Announces Key Appointments to Team to Drive CQ-001 through Clinical Trials
11 juin 2024 09h00 HE
|
CanaQuest Medical Corp.
Appointee, formerly with GW Pharma (subsidiary), brings extensive expertise in cannabinoid therapeutics, including the FDA-approved launch of cannabidiol (Epidiolex®) TORONTO, ON, June 11, 2024 ...
Qualigen Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Rule
12 déc. 2022 08h30 HE
|
Qualigen Therapeutics, Inc.
CARLSBAD, Calif., Dec. 12, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (“Qualigen” or “the Company,” Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for...
Qualigen Therapeutics, Inc. Reports Third Quarter 2022 Financial Results and Provides Corporate Update
15 nov. 2022 07h30 HE
|
Qualigen Therapeutics, Inc.
Q3 2022 FastPack ® sales increased approximately 25% year-over-yearCompany continues to execute on and advance core therapeutic programs CARLSBAD, Calif., Nov. 15, 2022 (GLOBE NEWSWIRE) -- Qualigen...
Life Sciences Market Growth & Share by 2029 | Company Profiles, Top Regions, Latest Technology, Investment Opportunities, Future Trends | Sales, Price, Revenue, Gross Margin, Cost Analysis
15 nov. 2022 01h34 HE
|
Absolute Reports Pvt Ltd
Pune, Nov. 15, 2022 (GLOBE NEWSWIRE) -- Life Sciences market report is knowledge and experience shared by industry experts to take correct decisions for manufacturers, new entrants, and industry...
Qualigen Therapeutics Announces Two Posters of Its RAS-Targeted Inhibitor Program at the National Cancer Institute
19 oct. 2022 09h00 HE
|
Qualigen Therapeutics, Inc.
Fourth RAS Initiative Symposium Highlights Preclinical Data in Solid Tumor Models CARLSBAD, Calif., Oct. 19, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified...
Qualigen Therapeutics to Present at LD Micro Main Event XV
18 oct. 2022 09h00 HE
|
Qualigen Therapeutics, Inc.
CARLSBAD, Calif., Oct. 18, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers...
Qualigen Therapeutics to Present Two Posters at the National Cancer Institute Fourth RAS Initiative Symposium
06 oct. 2022 08h00 HE
|
Qualigen Therapeutics, Inc.
CARLSBAD, Calif., Oct. 06, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers...
Qualigen Therapeutics to Present at the H.C. Wainwright Global Investment Conference
20 mai 2022 09h15 HE
|
Qualigen Therapeutics, Inc.
CARLSBAD, Calif., May 20, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers...
Qualigen Therapeutics Resumes Worldwide Distribution and Commercial Control Over FastPack®
05 avr. 2022 09h15 HE
|
Qualigen Therapeutics, Inc.
Company Prepared for Growth and Improved Profitability of its Diagnostics Business CARLSBAD, Calif., April 05, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified...
BioRestorative Therapies Announces Notice of Allowance for New Patent Application in Japan and Expansion of ThermoStem® IP Portfolio
02 févr. 2022 08h00 HE
|
BioRestorative Therapies, Inc
Notice of Allowance Grants Protection for Generating Implantable Three-Dimensional Scaffolds MELVILLE, N.Y., Feb. 02, 2022 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the “Company” or...